… Numerous resistance mechanisms characterize the development of CRPC. The review
focuses on AR-dependent pathways, including mechanisms of resistance to new agents. These …

… new cases of prostate cancer will be diagnosed in 2017 [1,2]. Overall survival (OS) for prostate
cancer … The 5-year survival rate for prostate cancer (all stages combined) has risen from …

… management of castration-resistant prostate cancer, with the development and approval
of many new drugs. The androgen receptor (AR) is the main driver in prostate cancer growth …

… Owing to this new understanding, several novel drugs have emerged for the treatment of …
androgens or target the androgen receptor (AR) directly. Abiraterone is an inhibitor of …

… There is an urgent need to determine the mechanisms of drug resistance, identify new …
Androgen receptor antagonists all bind to the LBD (23). Binding of the first-generation antagonists …

… Compensatory mechanisms leading to increased androgen receptor expression and activity
… models and mechanisms relevant to resistance to enzalutamide in human prostate cancer. …

… The extent to which AR-V7 (or AR-FL) is driving ABI/ENZ resistance will not be clear until
effective inhibitors are available. In addition to APA, there are several other new agents in …

… be over 180,000 new cases of prostate cancer in the USA … intricacies of androgen signaling
axis and the androgen receptor (… prostate cancer, as well as an adjuvant to localized prostate …

… mechanisms leading to therapy resistance against ADT and antagonists and AR bypass
mechanisms as … A new development to identify AR antagonists that target AR NTD is another …

… mechanisms behind castration resistance has led to the approval of novel oral androgen
receptor (AR) antagonists, such … current and emerging AR antagonists for the treatment of PCa. …